参考文献/References:
[1] 朱益佳, 宁明哲, 杨平, 等. 血清炎症性肠病抗体谱的检测对IBD 诊断及鉴别诊断的临床价值[J]. 现代检验医学杂志,2017,32(1):141-143.ZHU Yijia, NING Mingzhe, YANG Ping, et al.Clinical value of diagnosis and differential diagnosisof detection of serum inflammatory bowel diseaseantibody spectrum in IBD[J].Journal of ModernLaboratory Medicine, 2017, 32(1): 141-143.
[2] NAGAYAMA M, YANO T, ATARASHI K, et al. TH1cell-inducing Escherichia coli strain identified fromthe small intestinal mucosa of patients with Crohn’sdisease[J]. Gut Microbes, 2020, 12(1): 1788898.
[3] 汪海潮, 叶晨, 吴亚玲, 等. 克罗恩病患者合并肠外表现的临床特征及相关因素分析[J]. 中华炎性肠病杂志, 2020, 4(3):206-211.WANG Haichao, YE Chen, WU Yaling, et al. Clinicalcharacteristics and factors related to extraintestinalmanifestations in patients with Crohn’s disease [J].Chinese Journal of Inflammatory Bowel Diseases,2020, 4(3):206-211.
[4] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018 年, 北京)[J]. 中华消化杂志, 2018, 38(5):292-311.Inflammatory Bowel Disease Group, Chinese Societyof Gastroenterology,Chinese Medical Association.Chinese consensus on diagnosis and treatment ofinflammatory bowel disease (Beijing, 2018) [J].Chinese Journal of Digestion, 2018, 38(5):292-311.
[5] BEST W R, BECKTEL J M, SINGLETON J W,et al. Development of a Crohn’s disease activityindex. National cooperative crohn’s disease study[J].Gastroenterology, 1976, 70(3): 439-444.
[6] VALVANO M, MAGISTRONI M, MANCUSI A, etal. The usefulness of serum vitamin D levels in theassessment of IBD activity and response to biologics[J].Nutrients, 2021, 13(2): 323.
[7] BATTISTINI C, BALLAN R, HERKENHOFF M E,et al. Vitamin D modulates intestinal microbiota ininflammatory bowel diseases[J]. International Journalof Molecular Sciences, 2020, 22(1): 362.
[8] GISBERT-FERR?NDIZ L, SALVADOR P, ORTIZMASI?D, et al. A single nucleotide polymorphismin the vitamin D receptor gene is associated withdecreased levels of the protein and a penetrating patternin Crohn’s disease[J]. Inflammatory Bowel Diseases,2018, 24(7): 1462-1470.
[9] BENDIX M, DIGE A, J?RGENSEN S P, et al. Sevenweeks of high-dose vitamin D treatment reduces theneed for infliximab dose-escalation and decreasesinflammatory markers in Crohn’s disease during oneyearfollow-up[J]. Nutrients, 2021, 13(4): 1083.
[10] 尤国莉, 沈阳, 刘翠, 等. 维生素D 对克罗恩病患者铁调节蛋白和炎性因子的影响[J]. 国际消化病杂志,2020,40(5): 298-302,329.YOU Guoli, SHEN Yang, LIU Cui, et al. Effect ofvitamin D on iron regulatory protein and inflammatoryfactors in patients with Crohn’s disease [J].International Journal of Digestive Diseases, 2020,40(5):298-302,329.
[11] 张宪波,刘月皎,陈云峰.粪便钙卫蛋白在肠易激综合征和炎症性肠病鉴别诊断中的意义分析[J]. 现代检验医学杂志, 2021, 36(1): 124-127.ZHANG Xianbo, LIU Yuejiao, CHEN Yunfeng.Significance of fecal calprotectin in differentialdiagnosis of irritable bowel syndrome and inflammatorybowel disease [J]. Journal of Modern LaboratoryMedicine, 2021, 36(1): 124-127.
[12] ZHENG Wanwei, SONG Huan, LUO Zhongguang, etal. Acetylcholine ameliorates colitis by promoting IL-10 secretion of monocytic myeloid-derived suppressorcells through the nAChR/ERK pathway[J]. Proceedingsof the National Academy of Sciences of the UnitedStates of America, 2021, 118(11): e2017762118.
[13] DI LIBERTO D, SCAZZONE C, LA ROCCA G, etal. Vitamin D increases the production of IL-10 byregulatory T cells in patients with systemic sclerosis[J].Clinical and Experimental Rheumatology, 2020, 38(6):1276.
[14] 陈丹, 李骥, 张鑫垚, 等. 克罗恩病患者维生素D 水平与细胞因子的相关性研究[J]. 中华医学杂志,2020,100(10):757-762.CHEN Dan, LI Ji, ZHANG Xinyao, et al. Study ofthe correlation between vitamin D status and cytokinelevels in patients with Crohn’s disease[J]. NationalMedical Journal of China, 2020, 100(10):757-762.
[15] BERTANI L, CAVIGLIA G P, ANTONIOLI L, et al.Serum interleukin-6 and -8 as predictors of responseto vedolizumab in inflammatory bowel diseases[J].Journal of Clinical Medicine, 2020, 9(5): 1323.
[16] SU Yanzhuo, ZHAO Haomin. Predisposition ofinflammatory bowel disease is influenced by IL-8, IL-10, and IL-18 polymorphisms: a meta-analysis[J].International Archives of Allergy and Immunology,2020, 181(10): 799-806.
[17] 杨贝贝, 王许平, 王丹丹, 等.RANKL/OPG 系统及白细胞介素8 在炎症性肠病中的表达及作用研究[J].胃肠病学和肝病学杂志, 2019, 28(4):434-438.YANG Beibei, WANG Xuping, WANG Dandan, et al.RANKL / OPG system and interleukin-8 in inflammatorybowel disease [J]. Chinese Journal of Gastroenterologyand Hepatology, 2019, 28(4):434-438.
[18] 邓雳, 毛成荣, 赵家文. 血清TNF-α,IL-35 在炎症性肠病患者中的表达及临床价值[J]. 河北医药,2020, 42(2):295-297.DENG Li, MAO Chengrong, ZHAO Jiawen. Theexpression and clinical significance of serum TNF-αlpha and IL-35 in patients with inflammatory boweldisease [J]. Hebei Medical Journal, 2020, 42(2):295-297.
[19] 李青霞, 刘立新, 郭晓红. 抗TNF-α 制剂降阶梯治疗克罗恩病的疗效与安全性的Meta 分析[J]. 山西医科大学学报,2020,51(12):1383-1388.LI Qingxia, LIU Lixin, GUO Xiaohong. Efficacy andsafety of anti-TNF-αagents in the top-down treatmentof Crohn’s disease:a meta-analysis [J]. Journal ofShanxi Medical University, 2020, 51(12): 1383-1388.
[20] GREUTER T, MAILLARD M H, JUILLERAT P, et al.Therapeutic drug monitoring to guide clinical decisionmaking in inflammatory bowel disease patients withloss of response to anti-TNF: A delphi Technique-Basedconsensus[J]. Digestion, 2020, 101(6): 683-691.